The efficacy and safety of Diptptidyl peptidase-4 inhibitors combined with insulin in patients with autoimmune diabetes: A updated meta-analysis

The efficacy and safety of Diptptidyl peptidase-4 inhibitors combined with insulin in patients with autoimmune diabetes: A updated meta-analysis

Introduction: It is still controversial about the efficacy of Diptptidyl peptidase-4 (DPP4) inhibitors in the treatment of autoimmune diabetes, especially it is unclear whether different drugs have different efficacy for different subtypes of autoimmune diabetes. Aims: To evaluated the efficacy and...

Full description

Bibliographic Details
Main Authors:	Na Wang, Teng Yang, Xiuli Feng, Guofeng Wang, Liujing
Format:	Article
Language:	English
Published:	Elsevier 2024-06-01
Series:	Endocrine and Metabolic Science
Subjects:	DPP-4 inhibitors Autoimmune diabetes Beta cell function Hypoglycemia
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666396124000189

Similar Items

Emerging Role of Dipeptidyl Peptidase-4 in Autoimmune Disease
by: Jie Huang, et al.
Published: (2022-03-01)

Revolutionizing Treatment Strategies for Autoimmune and Inflammatory Disorders: The Impact of Dipeptidyl-Peptidase 4 Inhibitors
by: Rahim K, et al.
Published: (2024-03-01)

Dipeptidyl-Peptidase 4 Inhibitor-Induced Variants of Bullous Pemphigoid: A Case Series of Four Patients
by: Kamran Balighi, et al.
Published: (2022-11-01)

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
by: Chenkai Cui, et al.
Published: (2022-09-01)

Alogliptin – the new member of DPP-4 inhibitors class
by: Nina Aleksandrovna Petunina, et al.
Published: (2014-12-01)

Primary insulin autoimmune syndrome in an Italian woman: a case report
by: Antonio Balestrieri, et al.
Published: (2015-05-01)

UNEXPECTED ADVERSE REACTIONS OF THE DRUGS OF THE GROUP OF INHIBITORS OF DIPEPTIDYL PEPTIDASE-4
by: T. V. Romanova, et al.
Published: (2018-06-01)

Insulin Autoimmune Syndrome (Hirata Disease): A Comprehensive Review Fifty Years After Its First Description
by: Cappellani D, et al.
Published: (2020-04-01)

Insulin Autoimmune Syndrome as Part of Pre-Clinical LADA
by: Sutkowska E, et al.
Published: (2021-04-01)

Insulin autoimmune syndrome as a cause of recurrent hypoglycemia in a carbimazole user: a case report from Nepal
by: Pant V, et al.
Published: (2019-02-01)

Hyperglycaemia induced osteoporosis: Is there a hope with dipeptidyl peptidase-4 inhibitors?
by: Faraha Ahmed, et al.
Published: (2023-12-01)

Initial investigation of efficacy and safety of a new dipeptidyl peptidase-4 inhibitor, gosogliptin, for type 2 diabetes in Russia
by: Lyudmila Viktorovna Nedosugova, et al.
Published: (2014-12-01)

Insulin autoimmune syndrome induced by exogenous insulin injection: a four-case series
by: Yimin Shen, et al.
Published: (2019-12-01)

Comparison of safety and efficacy of glimepiride-metformin and vildagliptin- metformin treatment in newly diagnosed type 2 diabetic patients
by: Surendra Kumar
Published: (2021-01-01)

Insulin autoimmune syndrome induced by methimazole in a Korean girl with Graves' disease
by: Sun Hee Lee, et al.
Published: (2013-03-01)

Heterocyclic Compounds as Dipeptidyl Peptidase-IV Inhibitors with Special Emphasis on Oxadiazoles as Potent Anti-Diabetic Agents
by: Badrud Duza Mohammad, et al.
Published: (2022-09-01)

Dipeptidyl Peptidase Inhibition Enhances CD8 T Cell Recruitment and Activates Intrahepatic Inflammasome in a Murine Model of Hepatocellular Carcinoma
by: James M. Henderson, et al.
Published: (2021-11-01)

Inhibitors of dipeptidyl-peptidase-4: obvious and probable (literature review)
by: E. A. Ortenberg, et al.
Published: (2022-06-01)

The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence
by: Tianli Zhang, et al.
Published: (2021-12-01)

Effect of dipeptidyl peptidase 4 inhibitors on cardiovascular events in type-2 diabetes patients with renal impairment: A systematic review and meta-analysis
by: Maneesha Khalse, et al.
Published: (2020-01-01)

Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus
by: Karyekar CS, et al.
Published: (2013-04-01)

Coumarin-Based Sulfonamide Derivatives as Potential DPP-IV Inhibitors: Pre-ADME Analysis, Toxicity Profile, Computational Analysis, and In Vitro Enzyme Assay
by: Pallavi Kishor Vawhal, et al.
Published: (2023-01-01)

Ocular cicatricial pemphigoid following Dipeptidyl Peptidase-4 inhibitor use: A case report
by: Akifumi Matsumoto, et al.
Published: (2023-12-01)

Dipeptidyl-Peptidase-IV Inhibitors, Imigliptin and Alogliptin, Improve Beta-Cell Function in Type 2 Diabetes
by: Xu Liu, et al.
Published: (2021-09-01)

Urate-lowering effects of dipeptidyl peptidase-4 inhibitors
by: Taras S. Panevin, et al.
Published: (2020-12-01)

Quantitative Evaluation of Compliance with Recommendation for Sulfonylurea Dose Co-Administered with DPP-4 Inhibitors in Japan
by: Motonobu Sakaguchi, et al.
Published: (2012-09-01)

Clopidogrel as a Distinctive Cause of Insulin Autoimmune Syndrome: A Systematic Case Review
by: Chen S, et al.
Published: (2023-08-01)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis
by: Jonathan V. Mui, et al.
Published: (2021-10-01)

Effect of Dipeptidyl Peptidase-4 Inhibitors on Bone Metabolism and the Possible Underlying Mechanisms
by: Yinqiu Yang, et al.
Published: (2017-07-01)

Dipeptidyl peptidase-4 inhibitors or sodium glucose co-transporter-2 inhibitors as an add-on to insulin therapy: A comparative review
by: Awadhesh Kumar Singh, et al.
Published: (2016-01-01)

Clinical, Laboratory and Histological Features of Dipeptidyl Peptidase-4 Inhibitor Related Noninflammatory Bullous Pemphigoid
by: Ágnes Kinyó, et al.
Published: (2021-04-01)

Survey of Dipeptidyl Peptidase III Inhibitors: From Small Molecules of Microbial or Synthetic Origin to Aprotinin
by: Marija Abramić, et al.
Published: (2022-05-01)

Insulin autoimmune syndrome: A rare cause of hypoglycemia
by: Tejas M Maheshwari, et al.
Published: (2020-01-01)

Establishment of a selective evaluation method for DPP4 inhibitors based on recombinant human DPP8 and DPP9 proteins
by: Jinglong Liu, et al.
Published: (2014-04-01)

Non-Specific Inhibition of Dipeptidyl Peptidases 8/9 by Dipeptidyl Peptidase 4 Inhibitors Negatively Affects Mesenchymal Stem Cell Differentiation
by: Bárbara Torrecillas-Baena, et al.
Published: (2023-07-01)

Role of Dipeptidyl Peptidase 4 Inhibitors in Antidiabetic Treatment
by: Ruili Yin, et al.
Published: (2022-05-01)

Comparative risk of musculoskeletal adverse reactions among new users of dipeptidyl peptidase-4 inhibitors: A retrospective cohort study
by: Taehwan Park, et al.
Published: (2021-06-01)

Synthesis of (S)-1-(2-chloroacetyl)pyrrolidine-2-carbonitrile: A key intermediate for dipeptidyl peptidase IV inhibitors
by: Santosh K. Singh, et al.
Published: (2008-06-01)

Hypoglycemic Coma Caused by Methimazole-Induced Insulin Autoimmune Syndrome, a Case Study
by: He Y, et al.
Published: (2023-04-01)

A case of autoimmune hypoglycemia outside Japan: Rare, but in the era of expanding drug-list, important to suspect
by: Krishan Gopal, et al.
Published: (2013-01-01)